Moxifloxacin Hydrochloride Tablets, 400 mg

×

Overview

What is Moxifloxacin Hydrochloride Tablets, 400 mg?

Moxifloxacin hydrochloride is a synthetic antibacterial agent for oral administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. It is a slightly yellow to yellow powder or crystals, slightly hygroscopic substance with a molecular weight of 437.9. Its molecular formula is CHFNO*HCl and its chemical structure is as follows:

What does Moxifloxacin Hydrochloride Tablets, 400 mg look like?

What are the available doses of Moxifloxacin Hydrochloride Tablets, 400 mg?

Moxifloxacin Hydrochloride Tablets are available as dull red colored, caplet shaped, film coated tablets, debossed with "M" on one side and "400" on other side.

What should I talk to my health care provider before I take Moxifloxacin Hydrochloride Tablets, 400 mg?

• Based on animal data may cause fetal harm. () • Increased risk for severe tendon disorders further increased by concomitant corticosteroid therapy and increased risk of prolongation of the QT interval. (,, )

How should I use Moxifloxacin Hydrochloride Tablets, 400 mg?

Moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of(including multi-drug resistant [MDRSP]), methicillin-susceptible or .

MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC]≥ 2 mcg/mL), 2generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

The dose of moxifloxacin hydrochloride tablets is 400 mg (orally) once every 24 hours. The duration of therapy depends on the type of infection as described in Table 1.

a) Due to the designated pathogens

b) Sequential therapy (oral) may be instituted at the discretion of the physician.

c) Drug administration should begin as soon as possible after suspected or confirmed exposure to .

Conversion of Intravenous to Oral Dosing in Adults

Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with moxifloxacin hydrochloride injection may be switched to moxifloxacin hydrochloride tablets when clinically indicated at the discretion of the physician.

What interacts with Moxifloxacin Hydrochloride Tablets, 400 mg?

Sorry No Records found

What are the warnings of Moxifloxacin Hydrochloride Tablets, 400 mg?

Sorry No Records found

What are the precautions of Moxifloxacin Hydrochloride Tablets, 400 mg?

Sorry No Records found

What are the side effects of Moxifloxacin Hydrochloride Tablets, 400 mg?

Sorry No records found

What should I look out for while using Moxifloxacin Hydrochloride Tablets, 400 mg?

Moxifloxacin hydrochloride is contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antibacterials

Discontinue moxifloxacin hydrochloride immediately and avoid use of fluoroquinolones, including moxifloxacin hydrochloride, in patients who experience any of these serious adverse reactions

What might happen if I take too much Moxifloxacin Hydrochloride Tablets, 400 mg?

Single oral overdoses up to 2.8 g were not associated with any serious adverse events. In the event of acute overdose, Empty the stomach and maintain adequate hydration. Monitor ECG due to the possibility of QT interval prolongation. Carefully observe the patient and give supportive treatment. The administration of activated charcoal as soon as possible after oral overdose may prevent excessive increase of systemic moxifloxacin exposure. About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively.

How should I store and handle Moxifloxacin Hydrochloride Tablets, 400 mg?

Topiramate tablets should be stored in tightly-closed containers at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture. Caspofungin Acetate for Injection 50 mg is a lyophilized white to off-white powder/cake for intravenous infusion supplied in single-dose vials with an aluminum seal.NDC 67457-831-50Caspofungin Acetate for Injection 70 mg is a lyophilized white to off-white powder/cake for infusion in a vial with an aluminum seal.NDC 67457-832-70The lyophilized vials should be stored refrigerated at 2° to 8°C (36° to 46°F).Caspofungin Acetate for Injection 50 mg is a lyophilized white to off-white powder/cake for intravenous infusion supplied in single-dose vials with an aluminum seal.NDC 67457-831-50Caspofungin Acetate for Injection 70 mg is a lyophilized white to off-white powder/cake for infusion in a vial with an aluminum seal.NDC 67457-832-70The lyophilized vials should be stored refrigerated at 2° to 8°C (36° to 46°F).Caspofungin Acetate for Injection 50 mg is a lyophilized white to off-white powder/cake for intravenous infusion supplied in single-dose vials with an aluminum seal.NDC 67457-831-50Caspofungin Acetate for Injection 70 mg is a lyophilized white to off-white powder/cake for infusion in a vial with an aluminum seal.NDC 67457-832-70The lyophilized vials should be stored refrigerated at 2° to 8°C (36° to 46°F).Caspofungin Acetate for Injection 50 mg is a lyophilized white to off-white powder/cake for intravenous infusion supplied in single-dose vials with an aluminum seal.NDC 67457-831-50Caspofungin Acetate for Injection 70 mg is a lyophilized white to off-white powder/cake for infusion in a vial with an aluminum seal.NDC 67457-832-70The lyophilized vials should be stored refrigerated at 2° to 8°C (36° to 46°F).Caspofungin Acetate for Injection 50 mg is a lyophilized white to off-white powder/cake for intravenous infusion supplied in single-dose vials with an aluminum seal.NDC 67457-831-50Caspofungin Acetate for Injection 70 mg is a lyophilized white to off-white powder/cake for infusion in a vial with an aluminum seal.NDC 67457-832-70The lyophilized vials should be stored refrigerated at 2° to 8°C (36° to 46°F).

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents

Non-Clinical Toxicology

Moxifloxacin hydrochloride is contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antibacterials

Discontinue moxifloxacin hydrochloride immediately and avoid use of fluoroquinolones, including moxifloxacin hydrochloride, in patients who experience any of these serious adverse reactions

Drug Interactions - Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.

Fluoroquinolones, including moxifloxacin hydrochloride, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting moxifloxacin hydrochloride. Patients of any age or without pre-existing risk factors have experienced these adverse reactions Discontinue moxifloxacin hydrochloride immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including moxifloxacin hydrochloride, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.

The following serious and otherwise important adverse reactions are discussed in greater detail in the warnings and precautions section of the label: • Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects • Tendinitis and Tendon Rupture• Peripheral Neuropathy • Central Nervous System Effects • Exacerbation of Myasthenia Gravis • QT Prolongation • Other Serious and Sometimes Fatal Adverse Reactions • Hypersensitivity Reactions • Clostridium difficile-Associated Diarrhea • Blood Glucose Disturbances • Photosensitivity/Phototoxicity • Development of Drug Resistant Bacteria

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: